Acrux Limited (ASX: $ACR) launches dapsone 5%, gel in the United States

Acrux Limited (ASX: $ACR) has partnered with TruPharma to launch a generic of Dapsone 5%, Gel in the United States. The product is a prescription medicine used topically to treat acne vulgaris. Annual market sales for Dapsone 5%, Gel products for the 12 months ending October 2023 exceeded US$15 million as measured by IQVIA.

Executive Commentary on the Launch of Dapsone 5%, Gel

We are excited to partner with TruPharma to launch this topical prescription product in the United States. This is another product from the Acrux pipeline that is being commercialized. We look forward to announcing additional regulatory approvals and launches in the future.

Summary of Acrux's Launch of Dapsone 5%, Gel

Acrux Limited (ASX: $ACR) has announced the launch of a generic of Dapsone 5%, Gel in the United States in partnership with TruPharma. The product is used to treat acne vulgaris and has shown strong market sales. CEO and Managing Director, Michael Kotsanis, expressed excitement about the partnership and the commercialization of this product. Acrux looks forward to further regulatory approvals and launches in the future, leveraging its expertise in developing and commercializing pharmaceutical products.